Holen Sie sich die Stockscreener-App
5.97
0.51%
0.03
Handel nachbörslich:
5.98
0.01
+0.17%
Schlusskurs vom Vortag:
$5.94
Offen:
$5.95
24-Stunden-Volumen:
1.55M
Relative Volume:
0.33
Marktkapitalisierung:
$1.46B
Einnahmen:
$407.32M
Nettoeinkommen (Verlust:
$-61.60M
KGV:
-23.18
EPS:
-0.2576
Netto-Cashflow:
$-43.98M
1W Leistung:
+7.57%
1M Leistung:
-3.55%
6M Leistung:
+14.81%
1J Leistung:
+31.21%
1-Tages-Spanne:
$5.93
$6.085
1-Wochen-Bereich:
$5.685
$6.225
52-Wochen-Spanne:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
5.97 | 1.46B | 407.32M | -61.60M | -43.98M | -0.2576 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-09 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-09-03 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-06-18 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-02 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Could Ardelyx’s New CMO Reframe ARDX’s Long-Term Nephrology Pipeline Strategy? - Sahm
Ardelyx, Inc. (ARDX) stock price, news, quote and history - Yahoo Finance UK
Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings? - Yahoo Finance
Ardelyx CMO Appointment Tests Growth Plans For Tenapanor Based Therapies - Yahoo Finance
Ardelyx names Rajani Dinavahi as CMO - The Pharma Letter
Ardelyx, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Ardelyx (ARDX) CMO details 301,000 options at $6.11 and 201,000 shares - Stock Titan
Ardelyx President and CEO Sells 41,000 Shares for $243,000 - Yahoo Finance
Ardelyx President and CEO Sells 41,000 Shares for $243,000 - The Motley Fool
ARDX PE Ratio & Valuation, Is ARDX Overvalued - Intellectia AI
Assessing Ardelyx (ARDX) Valuation As New Chief Medical Officer Signals A Fresh Growth Phase - Sahm
Support Test: Is Ardelyx Inc stock forming a triangle pattern2026 Big Picture & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Ardelyx names Rajani Dinavahi as chief medical officer - investing.com
Ardelyx names Rajani Dinavahi as chief medical officer By Investing.com - Investing.com India
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx - The Manila Times
Ardelyx, Inc. (NASDAQ:ARDX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Trading Action: Can Ardelyx Inc stock double in the next yearMarket Risk Summary & Community Verified Watchlist Alerts - baoquankhu1.vn
Tech Rally: Is Ardelyx Inc affected by consumer sentiment2026 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
Ardelyx Investors Drop Appeal Over U-Turn on Medicare Program - Bloomberg Law News
Ardelyx, Inc. Stock Hits Day Low of $5.26 Amid Price Pressure - Markets Mojo
[SCHEDULE 13G/A] ARDELYX, INC. Amended Passive Investment Disclosure - Stock Titan
Ardelyx Stock Gaps Down Amid Weak Start and Market Concerns - Markets Mojo
Piper Sandler Maintains a Hold Rating on Ardelyx (ARDX) - MSN
Ardelyx's post-earnings decline attributed to concerns over Ibsrela outlook - MSN
Ardelyx gains after insider purchase, LPGA marketing deal - MSN
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
ARDX stock is down pre-market after Q4 earnings miss, so why did this firm just hike price target by 80%? - MSN
Can Ardelyx Inc stock outperform in a bear market2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
ARDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Insider Selling: Ardelyx (NASDAQ:ARDX) CEO Sells 41,666 Shares of Stock - MarketBeat
Raab, Ardelyx CEO, sells $243k in ARDX stock By Investing.com - Investing.com South Africa
Raab, Ardelyx CEO, sells $243k in ARDX stock - Investing.com
Ardelyx (ARDX) CEO exercises options, sells 41,666 shares under plan - Stock Titan
Ardelyx, Inc. Opens with 8.38% Gain, Contrasting Recent Performance Trends - Markets Mojo
Ardelyx, Inc. Hits Day High with Strong 14.49% Intraday Surge - Markets Mojo
ARDX Stock Price, Quote & Chart | ARDELYX INC (NASDAQ:ARDX) - ChartMill
Will Ardelyx’s (ARDX) IBSRELA Data Shift Its Competitive Position In IBS-C Treatments? - simplywall.st
Leerink Maintains Outperform on Ardelyx, Inc (ARDX) March 12, 2026 - Meyka
Leerink Partners reiterates Ardelyx stock rating on pipeline progress - Investing.com
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award - The Manila Times
Five kidney disease advocates honored for decades of patient support - Stock Titan
Breakout Move: How does Ardelyx Inc correlate with Nasdaq2026 Highlights & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Ardelyx Touts IBSRELA’s 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan - MarketBeat
Ardelyx at Leerink Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
ARDX: IBSRELA targets $1B sales by 2029, with pipeline and commercial growth fueled by strong execution - TradingView
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Weakness - Yahoo Finance
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ardelyx Inc-Aktie (ARDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | President & CEO |
Mar 16 '26 |
Sale |
5.84 |
41,666 |
243,329 |
1,816,448 |
| RAAB MICHAEL | President & CEO |
Feb 24 '26 |
Option Exercise |
0.99 |
20,833 |
20,625 |
1,877,819 |
| RAAB MICHAEL | President & CEO |
Feb 24 '26 |
Sale |
6.25 |
41,666 |
260,621 |
1,836,153 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):